ways is conserved throughout much of evolution. In the nematode Caenorhabditis ekgans programmed cell deaths are mediated by a mechanism controlled by the ced-9 gene; in mammal apoptosis can often be inhibited by expression of the bcl-2 gene. The ability of the human BCL2 gene to prevent cell deaths in C. elegans strongly suggests that bcl-2 and ced-9 are homologous genes. Although the process of cell death controlled by bcl-2 can occur in many cell types, there appears to be more than one physiological cell-death mechanism. Targets of cytotoxic T cells and cells deprived of growth factor both exhibit changes characteristic of apoptosis, such as DNA degradation. However, bcl-2 expression protects cells from factor withdrawal but fails to prevent cytotoxic T-cell killing. DNA degradation is, thus, not specific for any one cell-death mechanism. The ability of bcl-2 to protect cells from a wide variety of pathological, as well as physiological, stimuli indicates that many triggers can serve to activate the same suicide pathway, even some thought to cause necrosis, and not physiological cell death.
Cell death is an important physiological process in most, if not all, multicellular organisms, and they have evolved the molecular machinery necessary to implement it. There are many reasons why a multicellular organism would benefit from cell death, both during development and for homeostasis. For example, cells that are no longer necessary, or that are needed in only one sex, could be discarded. Descriptive and morphological studies have demonstrated the widespread occurrence and importance of cell deaths that occur as part of normal physiology (for reviews, see refs. 1-3).
During metamorphosis, cell death is readily apparent in both insects and amphibians, where the larval tissues must make way for those of the adult (4-7). In mammals, cell death is conspicuous from the very beginning of development. Cells of the endometrium die at the site of implantation of the blastocyst (8) , and in the developing nervous system, neurons that fail to make the correct connections die (9) . Cell death has been observed during development of the gut (10) and remodeling of the limb buds (11), cartilage (12) , and bones (13) .
Cell death is also used for homeostasis in developing and adult organisms. In the immune system B and T lymphocytes are removed when they fail to correctly rearrange their antigen receptors, when they are self-reactive, and if they fail to see foreign antigen (14) (15) (16) . Animals have evolved mechanisms to protect against viral infections by targeting infected cells for death. As new viral particles are produced by the host's cells, the most efficient way to stop virus production is for the host to kill its own virally infected cells through recognition of viral antigens by cytotoxic T cells (16, 17) .
Cell death may also be used to minimize the risk from cells frequently subjected to mutagenic chemicals or radiation. In the gut, where epithelial cells are exposed to carcinogens in the diet, cells die by physiological means (18, 19) . Similarly, in the skin, which is exposed to mutagenic UV radiation, physiological cell death is used to remove epidermal cells, rather than letting them passively slough away (20, 21) . As a further protection against malignancy, tumor necrosis factor can trigger the apoptotic death of transformed host cells (22, 23) .
In the reproductive system, examination of cyclical endometrium indicates that there is considerable loss of gland epithelial cells in the secretory, premenstrual, and menstrual phases (24) (25) (26) . Cell death regulated by steroid hormones is also apparent in the hormone-dependent cells of the prostate and breast (27) (28) (29) .
Dysregulation of Cell Death and Disease. With cell death being a normal part of so many different systems, the machinery that carries it out must be properly regulated to maximize benefit to the individual; when this regulation is disturbed, disease can result. Both inhibition of cell death and inappropriate cell death may be deleterious. For example, degenerative neurological diseases, such as Alzheimer disease and Parkinson disease, are associated with the premature death of particular subsets of neurons (30, 31) ; the death of T cells in AIDS resembles physiological cell death (32) (33) (34) ; and the rejection of transplants may, in part, be from physiological cell-death mechanisms (35) . Conversely, inhibition of cell death may contribute to disease in the immune system to allow persistence of self-reactive B and T cells, thus promoting autoimmune disease (14, 36, 37) . Most importantly, cancer may result when cells that fail to die undergo further mutations, leading to a transformed state (38) .
Morphological Analysis of Physiological Cell Death. Organisms use physiological cell death for a variety of reasons. We need to know how many different celldeath programs there are, whether and when they interact, and their precise molecular nature. In the past, cell death has been identified and studied descriptively.
The term "apoptosis" is often used to describe the physiological death of mammalian cells (1, 2 (39) . The same ladder is produced from the DNA of cells killed by cytotoxic T cells (40, 41) .
Necrosis, on the other hand, affects many adjoining cells (42) . It is characterized by cell swelling, with early loss of plasma-membrane integrity and major changes to the organelles, and the nu cleus tends to swell. Necrosis is accom panied by an inflammatory infiltrate ol phagocytic cells. DNA degradation, if il occurs, is a late event (42, 43) .
The term "programmed cell death" is commonly used synonymously with apoptosis. Apoptosis is more of a descriptive term, whereas programmed cell death implies that the decision to die was made cell-autonomously, independently of any other cells. Both terms suggest that the cell is an active participant in its own death. Unfortunately, the terms are not clearly defined, and different investigators have used different criteria in their classification. Evidence that inhibitors of macromolecular synthesis block cell death argue that the cell is, indeed, actively involved in its own demise (4, 39, (44) (45) (46) (47) (48) (49) , but in just as many cases macromolecular-synthesis inhibitors do not protect cells, so the cell-death machinery presumably already exists (50) (51) (52) (53) . To add to the confusion, there are numerous reports of actinomycin D and cyloheximide themselves triggering apoptosis (54) (55) (56) (57) (58) (59) (60) . Thus, the effect of macromolecular-synthesis inhibitors on cell death is of no help in determining whether it is physiological. The term "programmed cell death" is also problematic. If it is used strictly, referring only to purely cell-autonomous cell deaths, most physiological cell deaths would have to be excluded, as many cell deaths are triggered by other cells, or products of other cells.
The term "physiological cell death" indicates that the cell has died by a mechanism that has evolved specifically by the host to kill its own cells and probably includes most of what has been described as "programmed cell death" and "apoptosis." This term also includes cell deaths that may not exhibit some of the typical features of apoptosis, such as DNA degradation. There (51, (61) (62) (63) .
Genetic Analysis of Physiological Cell Death. Although descriptive studies of physiological cell death have identified -the phenomenon and demonstrated many -places where it occurs, they have not f been able to show how many different tphysiological cell-death processes there are, how they interact, or the molecular snature of their mechanism. Genetic and molecular experiments are now just beginning to provide some of the answers.
I
The nematode Caenorhabditis elegans has the best genetically characterized cell-death pathway. Over 100 of the 1090 somatic cells formed during development |die (64, 65) . Furthermore, the cells die in ta process resembling apoptosis (66) .
Fourteen genes have been identified that carry out various portions of the celldeath program. Some genes are involved in commitment, others carry out the sentence, and still others are required for engulfment and disposal of the corpse (67-69). Interestingly, one of these genes, nuc-J, encodes an endonuclease needed to digest the DNA of the cell corpse, after death has occurred. The ced-3 and ced4 genes are required in the dying cell for its death to occur, so they act cell-autonomously (70) . Programmed cell deaths are not seen in mutants lacking ced-3 or ced4, and they consequently have extra cells (67) . Furthermore, some cells rescued by the ced-3 or ced4 mutations have been shown to be functional. The action of the ced-3 and ced4 genes is antagonized by expression of ced-9 because cell death also fails to occur in activating mutants of ced-9 (69). Worms lacking a functional ced-9 gene arrest early in development, having only a few dozen to a few hundred cells at most, so ced-9 is required in many of the worm's cells. ced-9 is needed in these cells to prevent ced-3 and ced4 from killing the cell; all the defects due to ced-9 mutations are completely suppressed by mutations in ced-3 or ced4 (69) .
In mammals, the bcl-2 gene, which was first identified at the site oftranslocations common to follicular lymphomas, has I been found to regulate cell death. factor withdrawal, and (ii) cytotoxic T-cell killing, upon which bcl-2 has no effect. The early steps in apoptosis induced by factor deprivation differ from those triggered by cytotoxic T cells, despite the fact that they share a common final pathway featuring degradation of the DNA and loss of cytoplasmicmembrane integrity.
The ability of ced-9 to inhibit programmed cell deaths in C. elegans resembles the ability of the bcl-2 gene to inhibit apoptosis in mammalian cells (3, 69, 80) . Recent work has shown that expression of the human BCL2 gene in C. elegans prevents cell deaths that are normally mediated by ced-3 and ced4 (81) . This is strong evidence that bcl-2 is the homologue of ced-9 and implies that bcl-2 is likely to act in mammalian cells by inhibiting the effects of the mammalian homologues of ced-3 and ced4.
In addition to programmed cell deaths, cell killing or "murder" is also seen in nematodes. Death of one cell in C. elegans, the male linker cell, is not mediated by the ced cell-death pathway, as this cell is still engulfed and dies when ced-3 or ced4 are mutated (67) . However, the linker cell is not engulfed and fails to die when neighboring cells are ablated, indicating that its death is not cell-autonomous. Nevertheless, death of the linker cell is a physiological cell death, but just like cytotoxic cell killing in mammals, which is not prevented by bcl-2 (79) , linker cell death does not occur by a mechanism that can be inhibited by ced-9.
The final step in the process of programmed cell death in C. elegans is dissolution of the nucleus ofthe corpse. The nuc-J gene, which encodes a nuclease, is needed for this to occur (82) . Although it is not known whether the nuc-J gene in C.
elegans is equivalent to the calciumdependent endonucleases of mammalian cells, in both cases DNA degradation is likely to be a late step in cell death. In mammals, rapid DNA degradation is seen in physiological cell deaths carried out by cytotoxic cells, which are not blocked by bcl-2, as well as in cell deaths due to factor withdrawal, many of which are blocked by bcl-2 (79) . DNA degradation may be a shared final step in these physiological cell deaths, but it is not specific for any particular type.
The effects of bcl-2 are not limited to protecting cells from growth-factor withdrawal. bcl-2 protects mammalian cells from sodium azide, colchicine, DNA, RNA, and protein-synthesis inhibitors, steroids, heat shock, and irradiation (83) (84) (85) (86) (D.L.V., unpublished data). If bcl-2 acts like ced-9, it may function by inhibition of the putative mammalian homologues of ced-3 and ced4. Therefore, to cause rapid cell death, steroids, azide, :olchicine, and the other agents may acReuview: Vaux tivate the ced-3 and ced4 homologues, in addition to carrying out their immediate biochemical action, but at present it is not known whether the activation of any ced-3 and ced4 homologues is at the transcriptional, translational, or posttranslational levels. The physiological cell-death machinery that can be regulated by bcl-2 may constitute a "default" pathway that can be activated in many different ways. Some cells may not possess this cell-death mechanism and could only die by an alternative physiological cell-death pathway or by necrosis. Other cells may possess the cell-death mechanism that can be inhibited by bcl-2, but it may remain inactive unless triggered in some way. A third set of cells may harbor activated cell-death machinery but keep it in check with bcl-2. By analogy, the cell-death machinery, including the products of genes such as ced-3 and ced4, may act as a "gun." Cells lacking a gun can still be murdered, but to commit suicide these cells must use a different means. The gun, or cell-death mechanism, can be activated by pulling the "trigger," by withdrawal of growth factor, for instance. In some cases, cells may activate a preexisting gun, but in other cases cells may have to manufacture the gun before they can fire it. Macromolecular-synthesis inhibitors, such as actinomycin D, would inhibit cell death when the gun was not preexisting (4, 39) . In cases when macromolecular-synthesis inhibitors themselves induce cell death (54, 87) , the gun must already exist, and the macromolecular-synthesis inhibitors themselves must pull the trigger. bcl-2 and ced-9 can be thought of as a safety catch; pulling the trigger when the safety catch is engaged has no effect.
Ifa major default pathway for cells is to activate their cell-death machinery, then anything that threatens cell viability may lead to apoptosis. For example, there are many examples of growth-factor deprivation causing apoptosis (73) (74) (75) (88) (89) (90) . Blocking any of the steps in signal transduction, from the receptor down, would also trigger apoptosis, but few would argue that these genes are all cell-death inhibitor genes. Expression of any oncogene, such as v-src (91), v-fms (92), mutated p53 (93) , or v-abl (94) , which leads to transformation, or growth-factor independence, would also "inhibit apoptosis," even it did not act directly on the cell-death pathway. The same kind of argument can be made when a receptor triggers apoptosis. Thus, ifactivation ofa receptor, such as the tumor necrosis factor receptor (22) , steroid receptors (95, 96) , or antigen receptors (97, 98), triggers cell death, then blocking expression of any of the genes that act downstream, such as c-myc (99, 100), would inhibit cell death, but few of these genes would be directly involved in the cell-death pathway. In the extreme view, it could be argued that expression of practically any essential gene prevents apoptosis. Although this may be technically true, there may be many steps between loss of expression of these genes and activation of a default physiological death pathway.
Cell Death and Onogenesis. One of the most common malignancies of the blood cells, follicular lymphoma, is strongly associated with translocations that activate the BCL2 gene (101) . As BCL2 can inhibit programmed cell death (73) , the clone of cells bearing the translocation, which would otherwise have died, persists. Although BCL2 alone is insufficient to cause transformation (73), the surviving cells could provide the substrate for further genetic changes to conventional oncogenes, such as c-myc. Eventually a malignant clone could be produced. That this can, indeed, occur has been confirmed in transgenic mice that constitutively express bcl-2 in their lymphocytes (71, 72, 102, 103) .
Ifactivation of bcl-2 can lead to cancer, then inhibition of physiological cell death due to mutations to cell-death genes may result in the same outcome. If an individual were to inherit a mutated copy of a cell-death gene and then lose the other copy due to a somatic mutation, a clone of cells would be produced that could not implement that type of physiological cell death. These cells could then undergo additional genetic changes to conventional oncogenes, eventually leading to malignancy. A prediction of this model of failure of cell death resulting in oncogenesis is that cell-death effector genes, perhaps homologues of the C. elegans genes ced-3 and ced4, would act as tumorsuppressor genes.
Cell death is an important physiologic mechanism that has been conserved from nematodes to humans. When this mechanism is dysregulated, it may cause significant human disease. To understand physiological cell death we must uncover the molecular mechanisms by which it occurs. This search is just now beginning, especially through the application of molecular biological techniques and genetic experiments in well-defined model systems such as C. elegans.
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